Treatment of prostate cancer - The role of primary hormonal therapy

EAU Update Series

Volumn 1, Issue 1, 2003, Pages 32-39

  Anderson, John ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Adjuvant therapy; Antiandrogens; Bilateral orchidectomy; Luteinising hormone releasing hormone agonists; Luteinising hormone releasing hormone antagonists; Oestrogens; Prescribing guidelines; Prostate cancer

Indexed keywords

BUSERELIN; ESTROGEN; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; POLYESTRADIOL PHOSPHATE; TRIPTORELIN;

ALCOHOL INTOLERANCE; CANCER STAGING; CLINICAL TRIAL; DECISION MAKING; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; GYNECOMASTIA; HORMONAL THERAPY; HUMAN; LIVER TOXICITY; ORCHIECTOMY; PAIN; PROSTATE CARCINOMA; QUALITY OF LIFE; REVIEW; SIDE EFFECT;

EID: 2642557022     PISSN: 15709124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-9124(03)00007-2     Document Type: Article

References (44)

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
2. Kucuk O, Fisher E, Moinpour CM, Coleman D, Hussain MHA, Sartor AO, et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001;58:53-8.
3. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997;15:2928-38.
4. Kirby R. Treatment options for early prostate cancer. Urology 1998;52:948-62.
5. Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002;167:1952-6.
6. Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoagland HC. Anemia after orchiectomy. Am J Hematol 1998;59:230-3.
7. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 2002;90:427-32.
8. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. J Natl Cancer Inst Monogr 1988;7:165-70.
9. Hedlund PO, Henriksson P. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. Urology 2000;55:328-33.
10. Waymont B, Lynch TH, Dunn JA, Emtage LA, Arkell DG, Wallace DMA, et al. Phase III randomised study of Zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br J Urol 1992;69:614-20.
11. Bruchovsky N, Goldenberg SL, Akakura K, Rennie PS. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. Cancer 1993;72:1685-91.
12. Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PF, Smith Jr JA, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology 1995;46:220-6.
13. Schröder FH, Collette L, De Reijke TM, Whelan P. Members of the EORTC Genitourinary Group. Prostate cancer treated by anti-androgens: is sexual function preserved? Br J Cancer 2000;82:283-90.
14. Gillatt DA, Bolton CH, Chadwick D, Downs LG, Hopton MI, Gingell JC. Lipoprotein levels following treatment with cyproterone acetate or LHRH analogues. Br J Urol 1993;71:728-30.
15. de Voogt HJ, Smith PH, Pavone-Macaluso M, De Pauw M, Suciu S, Members of the European Organization for Research on Treatment of Cancer Urological Group. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986;135:303-7.
16. Pinganaud G. Cyproterone-induced hepatotoxicity. Ann Pharmacother 1995;29:634.
17. Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU Int 2001;87:47-56.
18. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TLJ, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000;164:1579-82.
19. McLeod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997;2:18-27.
20. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutaraide in prostatic carcinoma. N Engl J Med 1989; 321:419-24.
21. Denis LJ, Carneiro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, et al. EORTC GU Group and EORTC Data Center. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 1993;42:119-30.
22. Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, et al., Abarelix Study Group. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002;167:1670-4
23. The Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011-7.
24. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67:502-8.
25. Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997;32:391-6.
26. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, et al. A randomised comparison of 'Casodex™' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33:447-56.
27. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-8.
28. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24: 395-406.
29. Shipley WU, Thames HD, Sandier HM, Hanks GE, Zietman AL, Perez CA, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999; 281:1598-604.
30. Campbell T, Blasko J, Crawford ED, Forman J, Hanks G, Kuban D, et al. Clinical staging of prostate cancer: reproducibility and clarification of issues. Int J Cancer 2001;96:198-209.
31. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360: 103-8.
32. Grantors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998;159: 2030-4.
33. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937-46.
34. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
35. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8.
36. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
37. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002;168:429-35.
38. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002;90:561-6.
39. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood Jr DP, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167: 112-6.
40. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632-42.
41. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997;79:235-46.
42. Kirk D. Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation? BJU Int 2000;86(Suppl 3): 220.
43. Dawson NA. Intermittent androgen deprivation. Curr Oncol Rep 2000;2:409-16.
44. Paul R, Breul J. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. Drug Saf 2000;23:381-90.